What is Nexium Oral?
Nexium Oral strontium is used to treat conditions where there is too much acid in the stomach. It is used to treat duodenal and gastric ulcers, erosive esophagitis, gastroesophageal reflux disease (GERD), and the Zollinger-Ellison syndrome. Nexium Oral is also used with antibiotics (eg, amoxicillin, clarithromycin) to treat ulcers that are caused by the H. pylori bacteria. Nexium Oral strontium is also used to prevent stomach ulcers and stomach irritation in patients taking pain and arthritis drugs called NSAIDs, such as aspirin or ibuprofen, for long periods of time.
Nexium Oral strontium is a proton pump inhibitor (PPI). It works by decreasing the amount of acid that is produced by the stomach.
Nexium Oral strontium is available only with your doctor’s prescription.
Nexium Oral indications
Treatment of Gastroesophageal Reflux Disease (GERD)
Healing of Erosive Esophagitis
Nexium Oral Magnesium Delayed-Release Capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of Nexium Oral Magnesium Delayed-Release Capsules may be considered.
Maintenance of Healing of Erosive Esophagitis
Nexium Oral Magnesium Delayed-Release Capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months.
Symptomatic Gastroesophageal Reflux Disease
Nexium Oral Magnesium Delayed-Release Capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older.
Risk Reduction of NSAID-Associated Gastric Ulcer
Nexium Oral Magnesium Delayed-Release Capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months.
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Triple Therapy (Nexium Oral Magnesium Delayed-Release Capsules plus amoxicillin and clarithromycin): Nexium Oral Magnesium Delayed-Release Capsules, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted.
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
Nexium Oral Magnesium Delayed-Release Capsules are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.
How should I use Nexium Oral?
Use Nexium Oral delayed-release capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Nexium Oral delayed-release capsules comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Nexium Oral delayed-release capsules refilled.
- Take Nexium Oral delayed-release capsules by mouth on an empty stomach at least 1 hour before a meal.
- Swallow Nexium Oral delayed-release capsules whole. Do not break, crush, or chew before swallowing.
- If you have difficulty swallowing the capsule, you may add 1 tablespoon of applesauce to an empty bowl. Open the capsule and empty the pellets onto the applesauce. Mix the pellets with the applesauce and swallow the mixture right away. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. Do not chew or crush the pellets. Do not store the mixture for future use.
- If the patient is taking Nexium Oral delayed-release capsules through a nasogastric (NG) tube or gastric tube, follow the instructions for use in the extra patient leaflet.
- You may take antacids while you are using Nexium Oral delayed-release capsules if you are directed to do so by your doctor.
- Continue to take Nexium Oral delayed-release capsules even if you feel well. Do not miss any doses.
- If you miss a dose of Nexium Oral delayed-release capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Nexium Oral delayed-release capsules.
Uses of Nexium Oral in details
Use: Labeled Indications
Oral:
Nexium Oral magnesium and Nexium Oral strontium:
Gastroesophageal reflux disease (Rx only):
Healing of erosive esophagitis: Short-term (4 to 8 weeks) treatment of erosive esophagitis
Maintenance of healing of erosive esophagitis: Maintaining symptom resolution and healing of erosive esophagitis
Symptomatic gastroesophageal reflux disease: Short-term (4 to 8 weeks) treatment of symptomatic gastroesophageal reflux disease (GERD)
Helicobacter pylori eradication (Rx only): As part of a multidrug regimen for Helicobacter pylori eradication in patients with duodenal ulcer disease (active or history of within the past 5 years)
Risk reduction of nonsteroidal anti-inflammatory drug-associated gastric ulcer (Rx only): Prevention of gastric ulcers associated with continuous NSAID therapy in patients at risk (age ≥60 years and/or history of gastric ulcer)
Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (Rx only): Treatment (long-term) of pathological hypersecretory conditions including Zollinger-Ellison syndrome
Nexium Oral magnesium:
Heartburn (OTC labeling): Treatment of frequent heartburn (≥2 days per week).
IV: Nexium Oral sodium:
Gastroesophageal reflux disease (Rx only): Short-term (≤10 days) treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis in pediatric patients 1 month to 17 years of age and adults when oral therapy is not possible or appropriate
Risk reduction of ulcer rebleeding postprocedure (Rx only): Decrease the risk of rebleeding postendoscopy for acute bleeding gastric or duodenal ulcers in adults
Off Label Uses
Barrett esophagus
Data from a meta-analysis of observational studies evaluating acid suppressive therapy and the risk of esophageal adenocarcinoma or high-grade dysplasia in patients with Barrett esophagus showed that proton pump inhibitors were associated with a reduction in the risk of esophageal adenocarcinoma and high-grade dysplasia associated with Barrett esophagus; a longer duration of PPI use was associated with a greater protective effect.
Nexium Oral description
Each tablet contains 20 mg or 40 mg Nexium Oral (as magnesium trihydrate).
Each tablet contains Esomeprazole as enteric-coated pellets (MUPS).
Nexium Oral MUPS is a proton pump inhibitor. The active ingredient in Nexium Oral MUPS is Nexium Oral magnesium trihydrate, a substituted benzimidazole. Nexium Oral is the S-isomer of omeprazole. It is optically stable in vivo, with negligible conversion to the R-isomer. The chemical name is di-(S)-5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] sulfinyl] -1H- benzimidazole magnesium salt trihydrate.
Its molecular formula is C34H36N6O6S2Mg·3H2O and has a molecular weight of 767.2 (trihydrate).
Excipients/Inactive Ingredients: Glycerol monostearate 40-55, hyprolose, hypromellose, iron oxide (E 172) (Tablet 20 mg, reddish-brown CI 77491, yellow, CI 77492) (Tablet 40 mg, reddish-brown CI 77491), magnesium stearate, methacrylic acid ethyl acrylate copolymer (1:1) dispersion 30 percent, cellulose microcrystalline, synthetic paraffin, macrogols, polysorbate 80, crospovidone, sodium stearyl fumarate, sugar spheres (sucrose and maize starch), talc, titanium dioxide (E 171), triethyl citrate.
Nexium Oral 20 mg: Sucrose 28 mg.
Nexium Oral 40 mg: Sucrose 30 mg.
Nexium Oral dosage
Usual Adult Dose for Gastroesophageal Reflux Disease:
Nexium Oral Magnesium:
-20 mg orally once a day for 4 weeks
Nexium Oral Strontium:
-24.65 mg orally once a day for 4 to 8 weeks.
Comment:
-If symptoms do not resolve after 4 weeks, an additional 4 weeks may be considered.
GERD with Erosive Esophagitis:
Nexium Oral Sodium:
-20 mg or 40 mg IV injection once a day, over no less than 3 minutes; or IV infusion once a day, over no less than 10 to 30 minutes
Comment: Safety and efficacy of Nexium Oral sodium IV for Injection for more than 10 days have not been demonstrated.
Uses: Short term treatment of heartburn and symptomatic gastroesophageal reflux disease; short term treatment of GERD with erosive esophagitis, inclusively as an alternative to oral therapy, if unable to use oral route
Usual Adult Dose for Erosive Esophagitis:
Healing:
-Nexium Oral Magnesium: 20 to 40 mg orally once a day for 4 to 8 weeks
-Nexium Oral Strontium: 24.65 to 49.3 mg orally once a day for 4 to 8 weeks
-An additional 4 to 8 week course of therapy may be considered in patients not healed after initial treatment.
Maintenance of healing:
-Nexium Oral Magnesium: 20 mg orally once a day
-Nexium Oral Strontium: 24.65 mg orally once a daily
Comments:
-Nexium Oral Sodium injection may be used as an alternative to oral therapy, if unable to use oral route.
-Maintenance of healing: Controlled studies did not extend beyond six months.
Uses: Short-term treatment in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis; to maintain symptom resolution and healing of erosive esophagitis
Usual Adult Dose for Helicobacter pylori Infection:
Nexium Oral Magnesium:
Triple therapy:
-40 mg orally once a day for 10 days, along with amoxicillin 1000 mg and clarithromycin 500 mg orally twice a day for 10 days
Nexium Oral Strontium:
Triple therapy:
-49.3 mg orally once a day for 10 days, along with amoxicillin 1000 mg and clarithromycin 500 mg orally twice a day for 10 days
Comments:
-Susceptibility testing should be done in patients who fail therapy.
-If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted.
-Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Use: Triple therapy (Nexium Oral plus amoxicillin and clarithromycin): Treatment of H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori
Usual Adult Dose for NSAID-Induced Gastric Ulcer:
Nexium Oral Magnesium:
-20 mg to 40 mg orally once daily for up to 6 months
Nexium Oral Strontium:
-24.65 mg to 49.3 mg orally once a day for up to 6 months
Comment:
-Patients older than 60 years and/or with history of gastric ulcers are considered to be at risk for developing gastric ulcers.
-Controlled studies do not extend beyond 6 months
Use: Reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers.
Usual Adult Dose for Zollinger-Ellison Syndrome:
Nexium Oral Magnesium:
-40 mg orally twice a day
Nexium Oral Strontium:
-49.3 mg orally twice a day
Comment: Doses up to 240 mg daily have been used.
Use: Long term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome
Usual Adult Dose for Pathological Hypersecretory Conditions:
Nexium Oral Magnesium:
-40 mg orally twice a day
Nexium Oral Strontium:
-49.3 mg orally twice a day
Comment: Doses up to 240 mg daily have been used.
Use: Long term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome
Usual Adult Dose for Duodenal Ulcer Prophylaxis:
Nexium Oral Sodium:
-Initial dose: 80 mg IV infusion over 30 minutes
-Maintenance dose: 8 mg/hr IV continuous infusion for a total of 72 hours (includes initial 30 minute dose plus 71.5 hours of continuous infusion)
Comments:
-Intravenous therapy is aimed solely at the acute initial management of bleeding gastric or duodenal ulcers and does not constitute full treatment.
-Intravenous therapy should be followed by oral acid-suppressive therapy.
Use: Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy
Usual Adult Dose for Gastric Ulcer Prophylaxis:
Nexium Oral Sodium:
-Initial dose: 80 mg IV infusion over 30 minutes
-Maintenance dose: 8 mg/hr IV continuous infusion for a total of 72 hours (includes initial 30 minute dose plus 71.5 hours of continuous infusion)
Comments:
-Intravenous therapy is aimed solely at the acute initial management of bleeding gastric or duodenal ulcers and does not constitute full treatment.
-Intravenous therapy should be followed by oral acid-suppressive therapy.
Use: Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy
Usual Pediatric Dose for Gastroesophageal Reflux Disease:
Nexium Oral Magnesium:
Less than 1 year:
-Data not available
1 to 11 years:
-10 mg once a day for up to 8 weeks
-Comment: Doses over 1 mg/kg/day have not been studied.
12 to 17 years:
-20 mg once a day for 4 weeks
Nexium Oral Sodium:
GERD with Erosive Esophagitis:
Less than 1 month:
-Not recommended.
1 month to less than 1 year:
-0.5 mg/kg IV infused over 10 to 30 minutes
1 to 17 years:
-Less than 55 kg: 10 mg IV infused over 10 to 30 minutes
-55 kg or more: 20 mg IV infused over 10 to 30 minutes
Nexium Oral Strontium: Not recommended.
Uses: Short term treatment of symptomatic GERD; short term treatment of GERD with erosive esophagitis, inclusively as an alternative to oral therapy, if unable to use oral route
Usual Pediatric Dose for Erosive Esophagitis:
Nexium Oral Magnesium:
Healing:
Less than 1 year:
-Data not available
1 to 11 years:
-Less than 20 kg: 10 mg once a day for 8 weeks
-20 kg or more: 10 mg or 20 mg once a day for 8 weeks
12 to 17 years:
-20 or 40 mg once a day for 4 to 8 weeks
Comment: Doses over 1 mg/kg/day have not been studied.
Erosive Esophagitis due to acid-mediated GERD:
Less than 1 month:
-Data not available
1 month to less than 1 year old:
-3 kg to 5 kg: 2.5 mg once a day
-Greater than 5 kg to 7.5 kg: 5 mg once a day
-Greater than 7.5 kg to 12 kg: 10 mg once a day
Duration of therapy: For up to 6 weeks
Comment: Doses over 1.33 mg/kg/day have not been studied.
1 year and older:
-Data not available
Uses: Short-term treatment in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis; short term treatment of erosive esophagitis due to acid-mediated GERD in infants
Nexium Oral interactions
See also:
What other drugs will affect Nexium Oral?
Effects of Nexium Oral on the Pharmacokinetics of Other Drugs: The decreased intragastric acidity during treatment with Nexium Oral, might increase or decrease the absorption of drugs if the mechanism of absorption is influenced by gastric acidity. In common with the use of other inhibitors of acid secretion or antacids, the absorption of ketoconazole and itraconazole can decrease during treatment with Nexium Oral.
Nexium Oral inhibits CYP2C19, the major Nexium Oral-metabolising enzyme. Thus, when Nexium Oral is combined with drugs metabolised by CYP2C19 eg, diazepam, citalopram, imipramine, clomipramine, phenytoin, etc, the plasma concentrations of these drugs may be increased and a dose reduction could be needed. This should be considered especially when prescribing Nexium Oral for on-demand therapy.
Concomitant administration of Nexium Oral 30 mg resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam. Concomitant administration of Nexium Oral 40 mg resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with Nexium Oral is introduced or withdrawn.
Nexium Oral has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin, quinidine or warfarin.
Effects of Other Drugs on the Pharmacokinetics of Nexium Oral: Nexium Oral is metabolised by CYP2C19 and CYP3A4. Concomitant administration of Nexium Oral and a CYP3A4 inhibitor, clarithromycin (500 mg twice daily), resulted in a doubling of the exposure (AUC) to Nexium Oral. Dose adjustment of Nexium Oral is not required.
Nexium Oral side effects
See also:
What are the possible side effects of Nexium Oral?
Clinical Trials Experience With
Intravenous Nexium Oral
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
The safety of intravenous Nexium Oral is based on results from clinical trials conducted in four different populations including patients having symptomatic GERD with or without a history of erosive esophagitis (n=199), patients with erosive esophagitis (n=160), healthy subjects (n=204) and patients with bleeding gastric or duodenal ulcers (n=375).
Symptomatic GERD and Erosive Esophagitis Trials
The data described below reflect exposure to Nexium Oral I.V. for Injection in 359 patients. Nexium Oral I.V. for Injection was studied only in actively-controlled trials. The population was 18 to 77 years of age; 45% Male, 52% Caucasian, 17% Black, 3% Asian, 28% Other, and had either erosive reflux esophagitis (44%) or GERD (56%). Most patients received doses of either 20 or 40 mg either as an infusion or an injection. Adverse reactions occurring in ≥ 1% of patients treated with intravenous Nexium Oral (n=359) in clinical trials are listed below:
Table 2 : Adverse reactions occurring at an incidence ≥ 1% in the Nexium Oral I.V. group
| Adverse Reactions | % of patients Nexium OralIntravenous (n=359) |
| Headache | 10.9 |
| Flatulence | 10.3 |
| Nausea | 6.4 |
| Abdominal pain | 5.8 |
| Diarrhea | 3.9 |
| Mouth dry | 3.9 |
| Dizziness/vertigo | 2.8 |
| Constipation | 2.5 |
| Injection site reaction | 1.7 |
| Pruritus | 1.1 |
Intravenous treatment with Nexium Oral 20 and 40 mg administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of Nexium Oral.
Pediatric
A randomized, open-label, multi-national study to evaluate the pharmacokinetics of repeated intravenous doses of once daily Nexium Oral in pediatric patients 1 month to 17 years old, inclusive was performed. The safety results are consistent with the known safety profile of Nexium Oral and no unexpected safety signals were identified.
Risk Reduction of Rebleeding of Gastric or Duodenal Ulcers in Adults
The data described below reflect exposure to Nexium Oral I.V. for Injection in 375 patients. Nexium Oral I.V. for Injection was studied in a placebo-controlled trial. Patients were randomized to receive Nexium Oral I.V. for Injection (n=375) or placebo (n=389). The population was 18 to 98 years old; 68% Male, 87% Caucasian, 1% Black, 7% Asian, 4% other, who presented with endoscopically confirmed gastric or duodenal ulcer bleeding. Following endoscopic hemostasis, patients received either 80 mg Nexium Oral as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for a total treatment duration of 72 hours. After the initial 72-hour period, all patients received oral proton pump inhibitor (PPI) for 27 days.
Table 3 : Incidence (%) of adverse reactions that occurred in greater than 1% of patients within 72 hours after start of treatment*
| Number(%)of patients | ||
| Nexium Oral (n=375) | Placebo (n=389) | |
| Duodenal ulcer haemorrhage | 16 (4.3%) | 16 (4.1%) |
| Injection site reaction# | 16 (4.3%) | 2 (0.5) |
| Pyrexia | 13 (3.5%) | 11 (2.8%) |
| Cough | 4 (1.1%) | 1 (0.3%) |
| Dizziness | 4 (1.1%) | 3 (0.8%) |
| *Incidence ≥ 1% in the Nexium Oral group and greater than placebo group safety population #Injection site reactions included erythema, swelling, inflammation, pruritus, phlebitis, thrombophlebitis and superficial phlebitis. |
With the exception of injection site reactions described above, intravenous treatment with Nexium Oral administered as an injection or as an infusion was found to have a safety profile similar to that of oral administration of Nexium Oral.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Nexium Oral. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Postmarketing Reports - There have been spontaneous reports of adverse events with postmarketing use of Nexium Oral. These reports occurred rarely and are listed below by body system:
Blood And Lymphatic System Disorders: agranulocytosis, pancytopenia;
Eye Disorders: blurred vision;
Gastrointestinal Disorders: pancreatitis; stomatitis; microscopic colitis;
Hepatobiliary Disorders: hepatic failure, hepatitis with or without jaundice;
Immune System Disorders: anaphylactic reaction/shock;
Infections and Infestations: GI candidiasis;
Metabolism and nutritional disorders: hypomagnesemia;
Musculoskeletal And Connective Tissue Disorders: muscular weakness, myalgia, bone fracture;
Nervous System Disorders: hepatic encephalopathy, taste disturbance;
Psychiatric Disorders: aggression, agitation, depression, hallucination;
Renal and Urinary Disorders: interstitial nephritis;
Reproductive System and Breast Disorders: gynecomastia;
Respiratory, Thoracic and Mediastinal Disorders: bronchospasm;
Skin and Subcutaneous Tissue Disorders: alopecia, erythema multiforme, hyperhidrosis, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN, some fatal).
Other adverse events not observed with Nexium Oral, but occurring with omeprazole can be found in the omeprazole package insert, ADVERSE REACTIONS section.
Nexium Oral contraindications
See also:
What is the most important information I should know about Nexium Oral?
Nexium Oral is rapidly absorbed after oral doses, with peak plasma levels occurring after about 1-2 hrs. It is acid labile and an enteric-coated formulation has been developed. Bioavailability of Nexium Oral increases with both dose and repeated administration to about 68% and 89% for doses of 20 mg and 40 mg, respectively. Food delays and decreases the absorption of Nexium Oral, but this does not significantly change its effect of intragastric acidity. Nexium Oral is about 97% bound to plasma proteins. It is extensively metabolized in the liver by the cytochrome P450 (CYP450) isoenzyme CYP2C19 to hydroxy and desmethyl metabolites, which have no effect on gastric acid section. The remainder is metabolized by the CYP450 isoenzyme CYP3A4 to Nexium Oral sulfone. With repeated dosage, there is a decrease in first-pass metabolism and systemic clearance, probably caused by an inhibition of the CYP2C19 isoenzyme. However, there is no accumulation during once daily use. The plasma elimination half-life (t½) is about 1.3 hrs. Almost 80% of an oral dose is eliminated as metabolites in the urine, the remainder in the feces.
Active ingredient matches for Nexium Oral:
List of Nexium Oral substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Nexium/Nexium MUPS (Malaysia) | |
| Nexium DR-FC tab / MUPS 40 mg 14's (AstraZeneca) | $ 33.89 |
| Nexmezol (Estonia, Latvia, Lithuania) | |
| Nexonav (Philippines) | |
| Nexonav DR cap 40 mg 30's (XL Lab) | |
| Nexonav-40 (Philippines) | |
| NEXOPIL | |
| NEXOPIL 20 MG TABLET 1 strip / 10 tablets each (Psychotropics India Ltd) | $ 1.49 |
| NEXOPIL 40 MG TABLET 1 strip / 10 tablets each (Psychotropics India Ltd) | $ 0.25 |
| Nexopil 20mg Tablet (Psychotropics India Ltd) | $ 0.15 |
| Nexopil 40mg Tablet (Psychotropics India Ltd) | $ 0.02 |
| Nexopral (Bulgaria) | |
| Nexopraz 40 (Philippines) | |
| Nexopraz 40 EC tab 40 mg 100's (Saga Lab) | |
| Nexpes (Lithuania, Poland) | |
| Nexprazin (Brazil) | |
| Nexpro (Bangladesh, India, Myanmar) | |
| NEXPRO Capsule/ Tablet / 40mg / 15 units (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.83 |
| NEXPRO Capsule/ Tablet / 20mg / 15 units (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.50 |
| 20 mg x 15's (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.50 |
| 40 mg x 15's (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.83 |
| 40 mg x 1's (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.72 |
| Nexpro 20mg TAB / 15 (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.50 |
| Nexpro 40mg TAB / 15 (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.87 |
| Nexpro 40mg VIAL / 1 (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.72 |
| Nexpro 40 mg Tablet (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.06 |
| Nexpro 20 mg Tablet (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.03 |
| NEXPRO 20MG TABLET 1 strip / 15 tablets each (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.64 |
| NEXPRO 40MG TABLET 1 strip / 15 tablets each (Prima (Torrent Pharmaceuticals Ltd.)) | $ 1.24 |
| NEXPRO FAST 20MG TABLET 1 strip / 10 tablets each (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.78 |
| NEXPRO FAST 40MG TABLET 1 strip / 10 tablets each (Prima (Torrent Pharmaceuticals Ltd.)) | $ 1.11 |
| NEXPRO JUNIOR 1000 MG SACHET 1 packet / 1 sachet each (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.16 |
| NEXPRO IV INJECTION 1 vial / 1 injection each (Prima (Torrent Pharmaceuticals Ltd.)) | $ 1.02 |
| NEXPRO tab 20 mg x 15's (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.52 |
| NEXPRO tab 40 mg x 15's (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.92 |
| Nexpro 20mg Tablet (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.09 |
| Nexpro 40mg Tablet (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.12 |
| Nexpro 40mg Injection (Prima (Torrent Pharmaceuticals Ltd.)) | $ 1.12 |
| Nexpro 1000mg Granules (Prima (Torrent Pharmaceuticals Ltd.)) | $ 0.16 |
| Nexpro Fast (India) | |
| Nexpro Fast 20mg TAB / 15 (Torrent Pharmaceuticals Ltd.) | $ 0.50 |
| Nexpro Fast 40mg TAB / 15 (Torrent Pharmaceuticals Ltd.) | $ 0.87 |
| 20 mg x 15's (Torrent Pharmaceuticals Ltd.) | $ 0.50 |
| 40 mg x 15's (Torrent Pharmaceuticals Ltd.) | $ 0.87 |
| Nexpro Fast 40 mg Tablet (Torrent Pharmaceuticals Ltd.) | $ 0.08 |
| Nexpro Fast 20 mg Tablet (Torrent Pharmaceuticals Ltd.) | $ 0.06 |
| NEXPRO FAST film-coated tab 20 mg x 10's (Torrent Pharmaceuticals Ltd.) | $ 0.61 |
| NEXPRO FAST film-coated tab 40 mg x 10's (Torrent Pharmaceuticals Ltd.) | $ 0.89 |
See 1216 substitutes for Nexium Oral | |
References
- DailyMed. "ESOMEPRAZOLE STRONTIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Esomeprazole". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Esomeprazole". http://www.drugbank.ca/drugs/DB00736 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Nexium Oral are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Nexium Oral. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
